EU regulator recommends suspension of Pfizer's sickle cell disease treatment
Tweet
Share
E-mail
FILE PHOTO: Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
EMA said new data raise serious concerns about the safety of Oxbryta and added that the authorization, marketing and supply of the medicine be suspended until all the available data have been assessed in the ongoing review.
Late on Wednesday, Pfizer said it was withdrawing Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Germany's AfD eyes Saxony-Anhalt win as first step toward federal power
- Eleven bodies recovered after boat carrying migrants sinks off Tunisia
- Iran says new sanctions threatened by 'desperate' US will fail
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
